REGN's Pasatru wins FDA approval for FOP, cutting new HO lesions by 90% or more and reducing clinician-assessed flare-ups.

Pasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.

In August 2026, Regeneron Pharmaceuticals announced that the US FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and flare-ups in adults with fibrodysplasia ossificans progressiva, based on positive Phase 3 OPTIMA trial results. This approval adds a rare-disease monoclonal antibody to Regeneron’s portfolio, reinforcing the company’s focus on specialized, high-complexity immunology therapies. We’ll now examine how Pasatru’s FOP approval, as an ultra-rare...

Regeneron Pharmaceuticals stock has delivered a 43.0% return over the past year, yet the broader valuation checks point to a more mixed picture rather than a clear bargain or obvious overpricing. With recent partnership activity and pipeline progress in the spotlight, investors are weighing how much of that is already reflected in the current US$840.84 share price. The 43.0% one year return signals that the market has already repriced Regeneron Pharmaceuticals positively. The key issue for...

Franklin Biotechnology Discovery has a much higher 13% five-year annualized return than a biotech index ETF’s 5.3%

GlobalData highlighted EyePoint’s Duravyu as a notable drug set to enter the wet AMD market by 2034.

EyePoint's Duravyu misses the phase III wet AMD study's primary goal, sending shares down 67%, but shows lower treatment burden and durable disease control.

Duravyu, EyePoint’s candidate for wet age-related macular degeneration, misses the mark, but muddled trial data may be to blame.

They are fairly risky, but their potential upside is massive.

They are way more than just GLP-1 stocks.

Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology. On July 20, Biohaven announced a clinical supply agreement with Regeneron to evaluate the combination of BHV-1530 and Regeneron’s cemiplimab (Libtayo) in patients with solid tumors. BHV-1530’s novel topoisomerase I (TopoIx) payload generates immunogenic cell death and […]

BMS reveals plans for a new manufacturing hub in Houston, and Regeneron invests in startup developing a Dupixent competitor.

Infinimmune is targeting first-in-human studies with its longer-lasting monoclonal antibodies in 2027.

Regeneron's Eylea HD and Dupixent strength are fueling growth, while oncology gains and pipeline progress support its outlook.

Dividend, earnings and buybacks in focus Regeneron Pharmaceuticals (REGN) has given investors several fresh data points to consider after confirming a quarterly dividend, releasing second quarter and half year 2026 results, and updating on recent share repurchases. See our latest analysis for Regeneron Pharmaceuticals. Alongside the latest dividend and earnings update, Regeneron Pharmaceuticals’ recent share price return of 18.33% over 30 days and 9.72% over 90 days suggests momentum has...